Enhertu 100mg Injection (Trastuzumab Deruxtecan) – Complete Product Description

Enhertu 100mg Injection (Trastuzumab Deruxtecan) is a prescription targeted cancer medicine manufactured by Daiichi Sankyo. It contains trastuzumab deruxtecan, an antibody-drug conjugate (ADC) designed to target cancer cells that express the HER2 (human epidermal growth factor receptor 2) protein.

Enhertu combines a HER2-targeting monoclonal antibody with a potent chemotherapy payload. After binding to HER2 on cancer cells, the medicine is internalized and releases its active payload inside the cell, helping damage cancer-cell DNA and inhibit cancer growth.

Enhertu has important roles in the treatment of selected patients with HER2-positive and HER2-low cancers, depending on the cancer type, disease stage, biomarker status and applicable approved indication. It is used in several breast cancer settings and is also approved for selected patients with HER2-positive gastric or gastroesophageal junction cancer and other HER2-expressing solid tumors according to applicable treatment indications.

The product listed here is Enhertu 100mg Injection, manufactured by Daiichi Sankyo, with a pack size of 1 injection/vial. It is administered by intravenous infusion under the supervision of a qualified oncology healthcare professional.

Enhertu 100mg Injection – Product Information

Brand Name: Enhertu
Active Ingredient: Trastuzumab Deruxtecan
Strength: 100mg
Dosage Form: Powder for concentrate for solution for intravenous infusion
Route of Administration: Intravenous (IV) infusion
Manufacturer: Daiichi Sankyo
Pack Size: 1 injection/vial
Drug Class: Antibody-drug conjugate (ADC)
Target: HER2
Therapeutic Class: Targeted cancer therapy / Antineoplastic medicine
Prescription Status: Prescription medicine

What Is Enhertu 100mg Injection Used For?

Enhertu is used for selected patients with cancers that express HER2, depending on the approved indication and clinical circumstances.

It may be prescribed for certain patients with:

• HER2-positive breast cancer
• HER2-low breast cancer in appropriate treatment settings
• HER2-ultralow breast cancer in applicable settings
• HER2-positive unresectable or metastatic gastric or gastroesophageal junction cancer
• HER2-mutant unresectable or metastatic non-small cell lung cancer in selected patients
• Other HER2-expressing unresectable or metastatic solid tumors under applicable approved indications

The exact indication depends on the patient’s cancer type, HER2 testing results, previous treatment, disease stage and applicable treatment guidelines.

Enhertu for HER2-Positive Breast Cancer

HER2-positive breast cancer contains higher levels of the HER2 protein, which can promote cancer-cell growth.

Enhertu is an important treatment option for selected patients with HER2-positive breast cancer, including certain patients with unresectable or metastatic disease and patients who have received previous HER2-directed treatment.

The appropriate treatment regimen is determined by the treating oncologist based on the patient’s disease characteristics and previous therapies.

Enhertu for HER2-Low Breast Cancer

Some breast cancers have lower levels of HER2 expression and are classified as HER2-low.

Enhertu may be used in certain patients with unresectable or metastatic HER2-low breast cancer following appropriate previous treatment, depending on the applicable indication.

This has expanded the potential role of HER2-directed antibody-drug conjugate therapy beyond traditional HER2-positive disease.

Enhertu for Gastric and Gastroesophageal Junction Cancer

Enhertu may be used for selected patients with HER2-positive unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma who have received prior treatment, according to the applicable indication.

HER2 testing is important for identifying patients who may benefit from HER2-targeted therapy.

Enhertu for Lung Cancer

Enhertu may also be used in selected patients with HER2-mutant unresectable or metastatic non-small cell lung cancer (NSCLC).

The use of Enhertu in lung cancer depends on the presence of an appropriate HER2 mutation and the patient’s previous treatment history.

How Does Enhertu (Trastuzumab Deruxtecan) Work?

Enhertu is an antibody-drug conjugate, meaning it combines targeted antibody therapy with a potent cytotoxic drug.

The trastuzumab component recognizes and binds to HER2 on cancer cells.

After binding to HER2, the Enhertu complex is taken into the cancer cell. The drug is then broken down inside the cell, releasing the attached chemotherapy payload.

The released payload inhibits topoisomerase I, an enzyme involved in DNA replication. This causes DNA damage and can ultimately lead to cancer-cell death.

Enhertu also has a bystander effect, meaning the released payload can potentially affect nearby cancer cells, including cells with lower levels of HER2 expression.

This combination of targeted HER2 recognition and intracellular chemotherapy delivery makes Enhertu different from conventional chemotherapy.

Enhertu 100mg Dose and Administration

Enhertu is administered by intravenous infusion.

The recommended dose depends on the cancer being treated and the applicable treatment regimen. Common adult regimens include:

• 5.4 mg/kg every 3 weeks for several breast cancer and solid-tumor indications
• 6.4 mg/kg every 3 weeks for certain gastric or gastroesophageal junction cancer indications

The exact dose must be calculated according to the patient’s body weight and specific indication.

The 100mg vial is a presentation strength and does not necessarily represent the complete dose for one infusion. A patient may require multiple vials to achieve the prescribed dose.

Enhertu should be prepared and administered by qualified healthcare professionals.

It should not be self-injected.

Important Lung Safety Information

One of the most important risks associated with Enhertu is interstitial lung disease (ILD) and pneumonitis.

Patients should immediately report new or worsening:

• Cough
• Shortness of breath
• Difficulty breathing
• Fever
• Chest discomfort

Early recognition and management are important because severe or fatal ILD/pneumonitis can occur.

Patients with suspected ILD/pneumonitis require prompt medical evaluation, and treatment may need to be interrupted or permanently discontinued depending on severity.

Common Side Effects of Enhertu 100mg

Like all medicines, Enhertu can cause side effects.

Commonly reported adverse effects may include:

• Nausea
• Fatigue
• Vomiting
• Reduced appetite
• Constipation
• Hair loss
• Low blood cell counts
• Anemia
• Neutropenia
• Thrombocytopenia
• Increased liver enzymes
• Diarrhea
• Muscle or bone pain
• Headache

The frequency and severity of side effects may vary according to the treatment regimen and the patient’s overall health.

Serious Side Effects of Enhertu

Interstitial Lung Disease and Pneumonitis

ILD/pneumonitis is one of the most important serious risks associated with Enhertu.

Symptoms may include:

• New or worsening cough
• Shortness of breath
• Difficulty breathing
• Fever

Patients should contact their healthcare team immediately if respiratory symptoms develop.

Neutropenia and Other Blood Disorders

Enhertu can reduce blood-cell counts, including white blood cells, red blood cells and platelets.

This may increase the risk of:

• Infections
• Anemia-related fatigue
• Bleeding or bruising

Regular blood tests may be performed throughout treatment.

Nausea and Vomiting

Nausea is common with Enhertu. Preventive anti-nausea medicines may be prescribed before and after treatment to reduce symptoms.

Heart Problems

Because Enhertu contains a trastuzumab component, it may affect heart function.

Healthcare providers may assess left ventricular ejection fraction (LVEF) before and during treatment, particularly in patients with risk factors for cardiac dysfunction.

Patients should report symptoms such as:

• New or worsening shortness of breath
• Swelling of the legs
• Persistent cough
• Unusual fatigue
• Palpitations

Liver Problems

Changes in liver function tests can occur during treatment. Healthcare professionals may monitor liver enzymes and other laboratory parameters.

Precautions Before Using Enhertu 100mg

Tell your doctor before receiving Enhertu if you have:

• A history of lung disease
• Previous pneumonitis or interstitial lung disease
• Breathing problems
• Heart disease
• Reduced heart function
• Liver problems
• Previous severe reactions to trastuzumab-containing medicines
• Low blood cell counts
• An active infection

Tell your healthcare provider about all prescription medicines, over-the-counter medicines, supplements and previous cancer treatments.

Enhertu and HER2 Testing

HER2 testing plays an important role in determining whether Enhertu is appropriate for a particular cancer indication.

Depending on the cancer type, testing may evaluate:

• HER2 protein expression
• HER2 gene amplification
• HER2 mutation status

The appropriate testing method depends on the specific cancer and treatment indication.

Patients should discuss their pathology and biomarker results with their oncologist before treatment.

Enhertu During Pregnancy

Enhertu may cause fetal harm and should not be used during pregnancy unless specifically determined necessary by a specialist.

Women who can become pregnant should discuss effective contraception before starting treatment and during the recommended period following the final dose.

Patients who become pregnant while receiving Enhertu should contact their healthcare provider promptly.

Enhertu and Breastfeeding

Breastfeeding is generally not recommended during Enhertu treatment because of the potential risk to the infant.

Patients should discuss breastfeeding with their oncologist before starting treatment and follow medical advice regarding when breastfeeding can safely resume.

Enhertu 100mg Storage

Enhertu is a specialized biological medicine requiring appropriate temperature-controlled storage.

The unopened vial should be stored according to the manufacturer’s recommended conditions and protected from light.

Do not freeze or shake Enhertu.

Reconstitution, dilution and preparation for intravenous infusion must be performed by qualified healthcare professionals using appropriate sterile procedures.

Enhertu 100mg Injection Price in Pakistan

The Enhertu 100mg Injection price in Pakistan may vary depending on availability, supplier, import costs, exchange rates and prevailing market conditions.

For the latest Enhertu 100mg price in Pakistan, customers can contact MedicineWalyDost.com to check current availability and pricing.

As Enhertu is a specialized oncology biological medicine, pricing can change based on market availability. Customers should confirm the current price before ordering.

Why Choose Enhertu 100mg Injection?

Enhertu contains trastuzumab deruxtecan, an advanced antibody-drug conjugate designed to deliver a potent cytotoxic payload directly to HER2-expressing cancer cells.

Its targeted mechanism combines HER2 recognition with intracellular delivery of a topoisomerase I inhibitor, providing a distinct approach to cancer treatment.

The Daiichi Sankyo Enhertu 100mg Injection presentation is supplied as a 100mg vial and listed here with a pack size of 1 injection/vial.

Enhertu should only be used following appropriate cancer diagnosis, biomarker assessment and specialist treatment planning.

Frequently Asked Questions About Enhertu 100mg

What is Enhertu 100mg Injection?

Enhertu 100mg Injection is a prescription cancer medicine containing trastuzumab deruxtecan, an antibody-drug conjugate targeting HER2.

What is the generic name of Enhertu?

The generic name is trastuzumab deruxtecan.

Who manufactures Enhertu 100mg?

The manufacturer of the product listed here is Daiichi Sankyo.

What is the pack size of Enhertu 100mg?

The pack size is 1 injection/vial.

What is Enhertu used for?

Enhertu is used in selected patients with certain HER2-positive, HER2-low, HER2-ultralow or HER2-mutant cancers, depending on the specific cancer type and approved indication.

How is Enhertu 100mg administered?

Enhertu is administered by intravenous infusion by a qualified healthcare professional.

Is 100mg the complete Enhertu dose?

Not necessarily. Enhertu dosing is generally based on body weight and the specific cancer indication. Multiple 100mg vials may be required to achieve the prescribed dose.

Is Enhertu chemotherapy?

Enhertu is an antibody-drug conjugate (ADC). It combines a HER2-targeting antibody with a potent chemotherapy payload, making it different from conventional chemotherapy alone.

What is the most serious risk of Enhertu?

One of the most important serious risks is interstitial lung disease (ILD) or pneumonitis, which can be severe or life-threatening. New or worsening respiratory symptoms should be reported immediately.

Does Enhertu affect the heart?

Enhertu may affect heart function. Healthcare professionals may monitor cardiac function during treatment, particularly in patients with relevant risk factors.

Does Enhertu cause hair loss?

Hair loss can occur during Enhertu treatment, although the frequency varies among patients.

Can Enhertu be purchased without a prescription?

Enhertu is a specialized prescription oncology medicine and should only be used under the supervision of a qualified oncologist.

Order Enhertu 100mg Injection in Pakistan

Looking for Enhertu 100mg Injection (Trastuzumab Deruxtecan) by Daiichi Sankyo in Pakistan?

MedicineWalyDost.com provides access to specialized prescription medicines and oncology products. Contact us to check the latest Enhertu 100mg price, availability and ordering information.

Before ordering, confirm the brand, strength, active ingredient, manufacturer, pack size and prescription requirements with your doctor or pharmacist.

Order Enhertu 100mg Injection from MedicineWalyDost.com and contact us today for current availability and pricing.

Important Medical Disclaimer

Enhertu 100mg Injection is a prescription oncology biological medicine. This product description is intended for educational and e-commerce purposes only and does not replace professional medical advice. Trastuzumab deruxtecan can cause serious or potentially life-threatening adverse effects, particularly interstitial lung disease/pneumonitis, and requires specialist supervision. Do not start, stop or modify treatment without consulting your treating oncologist.

---